Celldex Therapeutics Inc (CLDX) 29.39 $CLDX Bri
Post# of 64200
Posted On: 03/08/2015 5:28:47 PM
Celldex Therapeutics Inc (CLDX) 29.39 $CLDX
Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 3:45PM CST
Bristol-Myers Squibb announced encouraging data from a phase III study evaluating a once-daily combination of Daklinza and Gilead Sciences Inc.'s Sovaldi.
GILD: 101.81 (-1.61), CLDX: 29.39 (-0.39), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93)
Why Celldex Therapeutics, Inc. Is Soaring
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 04, 11:59AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What's happening: Shares in the clinical stage biotech ...
CLDX: 29.39 (-0.39)
Celldex's underwriters exercise option to purchase a further 1.088m common shares
M2 - Mon Mar 02, 5:04AM CST
Biopharmaceutical company Celldex Therapeutics (NasdaqGS:CLDX) revealed on Friday that the underwriters of its public offering have exercised in full their option to purchase an additional 1,087,500 shares of common stock at the public offering price of USD24.00.
CLDX: 29.39 (-0.39)
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.80 (-0.11), VRX: 198.71 (-5.24), ACT: 289.92 (-5.78), PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), CAH: 87.01 (-1.94), CLDX: 29.39 (-0.39), HSP: 87.90 (+0.05), AGN: 233.51 (-1.90), JNJ: 100.11 (-2.41), ATOS: 1.97 (-0.04), ONVO: 5.59 (-0.13), PTCT: 71.13 (-1.59), SNY: 47.42 (-0.94), PTLA: 41.72 (-0.13), INCY: 90.00 (-1.97), PFE: 33.97 (-0.50), CPHR: 11.67 (-0.33), MYL: 55.44 (-1.25), AMGN: 154.88 (-4.72), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), NKTR: 13.02 (-0.28), OMER: 26.14 (-0.21), DVA: 77.63 (+0.70), GILD: 101.81 (-1.61), SGEN: 35.32 (-0.28), ACHN: 11.39 (+0.40), MRK: 56.84 (-1.14), TEVA: 56.40 (-0.11), BIL: 45.72 (-0.01), ARIA: 8.08 (-0.17), NVS: 97.46 (-1.49)
Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences
at The Street - Fri Feb 27, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 417.63 (-7.98), CLDX: 29.39 (-0.39), RCPT: 140.09 (-1.10), EXAS: 24.50 (+2.07)
The Best Way To Capitalize On Celldex Therapeutics' Upside
Investing Healthcare - at Seeking Alpha - Thu Feb 26, 3:50PM CST
CLDX: 29.39 (-0.39)
Celldex prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 6:38AM CST
CLDX: 29.39 (-0.39)
Seattle Genetics: The Long View
William Meyers - at Seeking Alpha - Wed Feb 25, 6:56AM CST
SGEN: 35.32 (-0.28), CLDX: 29.39 (-0.39)
Celldex Therapeutics'. (CLDX) CEO Anthony Marucci on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 1:53PM CST
CLDX: 29.39 (-0.39)
Celldex Therapeutics (CLDX) Stock Rises Today on Rintega FDA Designation, Fourth-Quarter Earnings
at The Street - Tue Feb 24, 11:39AM CST
Shares of Celldex Therapeutics (CLDX) were up in afternoon trading Tuesday after the company's drug Rintega received breakthrough designation therapy from the U.S. Food and Drug Administration on Monday.
CLDX: 29.39 (-0.39)
Celldex reports 4Q loss
Automated Insights - Tue Feb 24, 10:58AM CST
HAMPTON, N.J. (AP) _ Celldex Therapeutics Inc. (CLDX) on Tuesday reported a loss of $31.8 million in its fourth quarter.
CLDX: 29.39 (-0.39)
Celldex Therapeutics Inc. Q4 Earnings Overshadowed by FDA News
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 24, 10:38AM CST
Celldex Therapeutics reported its fourth-quarter earnings results before the market opened on Tuesday. But hardly anyone really cared. Plenty of people care about how Celldex is doing, as evidenced by the stock's 16% jump on Monday. However, one...
CLDX: 29.39 (-0.39), GSK: 46.73 (-0.87)
Celldex Therapeutics (CLDX) Wider-than-Expected Loss in Q4 - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:23AM CST
Celldex Therapeutics (CLDX) Wider-than-Expected Loss in Q4
CLDX: 29.39 (-0.39)
Celldex Therapeutics (CLDX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 24, 6:55AM CST
CLDX: 29.39 (-0.39)
Celldex misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 6:01AM CST
CLDX: 29.39 (-0.39)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 4:30PM CST
AMT: 96.61 (-2.63), UTHR: 160.65 (-0.71), TREX: 51.00 (-2.11), GLDD: 5.87 (-0.11), THRM: 45.78 (-1.26), SUI: 66.37 (-0.63), CYRN: 2.54 (-0.12), EXLS: 34.76 (-0.29), AIXG: 7.95 (-0.11), WLK: 67.21 (-1.63), COT: 9.67 (-0.14), SPAR: 4.82 (-0.07), SAH: 23.52 (-0.50), DYAX: 15.64 (-0.05), GTLS: 35.47 (-1.16), VAL: 86.59 (-0.67), SHOO: 35.12 (-0.50), CBRL: 147.51 (-3.65), WPC: 65.92 (-2.63), EXPD: 47.66 (-0.31), TRXC: 2.73 (-0.09), WEN: 10.84 (-0.20), CEQP: 6.18 (-0.35), CMLP: 14.50 (-0.51), CLDT: 28.02 (-1.02), CLDX: 29.39 (-0.39), SAFM: 82.30 (-1.32), M: 62.98 (-0.21), SPWR: 33.56 (-0.04), WIN: 7.67 (-0.09), DCI: 37.52 (-0.34), CRNT: 1.25 (unch), IART: 59.15 (-0.96), DPZ: 100.87 (-2.51), CRZO: 46.63 (-1.65), ECL: 114.69 (-2.08), BMO: 60.40 (-0.63), DAKT: 10.03 (-0.18), HD: 114.45 (-1.46), SHLX: 38.74 (-0.34), NEO: 4.91 (-0.05), EXAS: 24.50 (+2.07), ALKS: 68.19 (-3.03), MNKD: 5.47 (-0.26), FDML: 13.24 (-0.02), DRH: 13.52 (-0.35), IPXL: 39.08 (-1.00), ZINC: 12.39 (-0.28), VSI: 41.68 (+0.76), PLL: 100.17 (-1.87), RLGY: 45.46 (-0.94), ODP: 9.30 (-0.04), PF: 36.81 (-0.25), CMCSA: 60.37 (+0.04), PCRX: 96.63 (-1.77), TOL: 36.92 (-1.00)
Will Celldex Therapeutics (CLDX) Disappoint This Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 4:00PM CST
Celldex Therapeutics (CLDX) is expected to report fourth-quarter 2014 results on Feb 24.
IPXL: 39.08 (-1.00), ISIS: 70.44 (-1.32), CLDX: 29.39 (-0.39), BMY: 65.12 (-0.93)
Why Shares of Celldex Therapeutics Inc. Skyrocketed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Feb 23, 2:24PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celldex Therapeutics shot nearly 20%...
CLDX: 29.39 (-0.39)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 11:44AM CST
HNH: 43.18 (-1.34), MELA: 1.83 (+0.02), CYBR: 59.78 (-3.09), OTIV: 1.24 (-0.02), CERU: 8.12 (+0.14), CLDX: 29.39 (-0.39), BIOC: 3.10 (-0.26), AXN: 1.49 (+0.37), SPPI: 6.26 (+0.02), NSLP: 7.65 (-0.05), RIGL: 3.56 (+0.26), VRTB: 3.61 (+0.30), WBAI: 14.50 (+0.70), BLCM: 24.48 (+0.13), SFY: 3.12 (-0.12), TSEM: 17.50 (-0.31), PTCT: 71.13 (-1.59), HOTR: 2.04 (-0.03), PRTA: 26.12 (-0.46), DGLY: 12.81 (+0.43)
CellDex Leaves Them All Behind
Scrying Biotech - at Seeking Alpha - Mon Feb 23, 10:02AM CST
CLDX: 29.39 (-0.39)
Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 3:45PM CST
Bristol-Myers Squibb announced encouraging data from a phase III study evaluating a once-daily combination of Daklinza and Gilead Sciences Inc.'s Sovaldi.
GILD: 101.81 (-1.61), CLDX: 29.39 (-0.39), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93)
Why Celldex Therapeutics, Inc. Is Soaring
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 04, 11:59AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What's happening: Shares in the clinical stage biotech ...
CLDX: 29.39 (-0.39)
Celldex's underwriters exercise option to purchase a further 1.088m common shares
M2 - Mon Mar 02, 5:04AM CST
Biopharmaceutical company Celldex Therapeutics (NasdaqGS:CLDX) revealed on Friday that the underwriters of its public offering have exercised in full their option to purchase an additional 1,087,500 shares of common stock at the public offering price of USD24.00.
CLDX: 29.39 (-0.39)
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.80 (-0.11), VRX: 198.71 (-5.24), ACT: 289.92 (-5.78), PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), CAH: 87.01 (-1.94), CLDX: 29.39 (-0.39), HSP: 87.90 (+0.05), AGN: 233.51 (-1.90), JNJ: 100.11 (-2.41), ATOS: 1.97 (-0.04), ONVO: 5.59 (-0.13), PTCT: 71.13 (-1.59), SNY: 47.42 (-0.94), PTLA: 41.72 (-0.13), INCY: 90.00 (-1.97), PFE: 33.97 (-0.50), CPHR: 11.67 (-0.33), MYL: 55.44 (-1.25), AMGN: 154.88 (-4.72), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), NKTR: 13.02 (-0.28), OMER: 26.14 (-0.21), DVA: 77.63 (+0.70), GILD: 101.81 (-1.61), SGEN: 35.32 (-0.28), ACHN: 11.39 (+0.40), MRK: 56.84 (-1.14), TEVA: 56.40 (-0.11), BIL: 45.72 (-0.01), ARIA: 8.08 (-0.17), NVS: 97.46 (-1.49)
Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences
at The Street - Fri Feb 27, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 417.63 (-7.98), CLDX: 29.39 (-0.39), RCPT: 140.09 (-1.10), EXAS: 24.50 (+2.07)
The Best Way To Capitalize On Celldex Therapeutics' Upside
Investing Healthcare - at Seeking Alpha - Thu Feb 26, 3:50PM CST
CLDX: 29.39 (-0.39)
Celldex prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 6:38AM CST
CLDX: 29.39 (-0.39)
Seattle Genetics: The Long View
William Meyers - at Seeking Alpha - Wed Feb 25, 6:56AM CST
SGEN: 35.32 (-0.28), CLDX: 29.39 (-0.39)
Celldex Therapeutics'. (CLDX) CEO Anthony Marucci on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 1:53PM CST
CLDX: 29.39 (-0.39)
Celldex Therapeutics (CLDX) Stock Rises Today on Rintega FDA Designation, Fourth-Quarter Earnings
at The Street - Tue Feb 24, 11:39AM CST
Shares of Celldex Therapeutics (CLDX) were up in afternoon trading Tuesday after the company's drug Rintega received breakthrough designation therapy from the U.S. Food and Drug Administration on Monday.
CLDX: 29.39 (-0.39)
Celldex reports 4Q loss
Automated Insights - Tue Feb 24, 10:58AM CST
HAMPTON, N.J. (AP) _ Celldex Therapeutics Inc. (CLDX) on Tuesday reported a loss of $31.8 million in its fourth quarter.
CLDX: 29.39 (-0.39)
Celldex Therapeutics Inc. Q4 Earnings Overshadowed by FDA News
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 24, 10:38AM CST
Celldex Therapeutics reported its fourth-quarter earnings results before the market opened on Tuesday. But hardly anyone really cared. Plenty of people care about how Celldex is doing, as evidenced by the stock's 16% jump on Monday. However, one...
CLDX: 29.39 (-0.39), GSK: 46.73 (-0.87)
Celldex Therapeutics (CLDX) Wider-than-Expected Loss in Q4 - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:23AM CST
Celldex Therapeutics (CLDX) Wider-than-Expected Loss in Q4
CLDX: 29.39 (-0.39)
Celldex Therapeutics (CLDX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 24, 6:55AM CST
CLDX: 29.39 (-0.39)
Celldex misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 6:01AM CST
CLDX: 29.39 (-0.39)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 4:30PM CST
AMT: 96.61 (-2.63), UTHR: 160.65 (-0.71), TREX: 51.00 (-2.11), GLDD: 5.87 (-0.11), THRM: 45.78 (-1.26), SUI: 66.37 (-0.63), CYRN: 2.54 (-0.12), EXLS: 34.76 (-0.29), AIXG: 7.95 (-0.11), WLK: 67.21 (-1.63), COT: 9.67 (-0.14), SPAR: 4.82 (-0.07), SAH: 23.52 (-0.50), DYAX: 15.64 (-0.05), GTLS: 35.47 (-1.16), VAL: 86.59 (-0.67), SHOO: 35.12 (-0.50), CBRL: 147.51 (-3.65), WPC: 65.92 (-2.63), EXPD: 47.66 (-0.31), TRXC: 2.73 (-0.09), WEN: 10.84 (-0.20), CEQP: 6.18 (-0.35), CMLP: 14.50 (-0.51), CLDT: 28.02 (-1.02), CLDX: 29.39 (-0.39), SAFM: 82.30 (-1.32), M: 62.98 (-0.21), SPWR: 33.56 (-0.04), WIN: 7.67 (-0.09), DCI: 37.52 (-0.34), CRNT: 1.25 (unch), IART: 59.15 (-0.96), DPZ: 100.87 (-2.51), CRZO: 46.63 (-1.65), ECL: 114.69 (-2.08), BMO: 60.40 (-0.63), DAKT: 10.03 (-0.18), HD: 114.45 (-1.46), SHLX: 38.74 (-0.34), NEO: 4.91 (-0.05), EXAS: 24.50 (+2.07), ALKS: 68.19 (-3.03), MNKD: 5.47 (-0.26), FDML: 13.24 (-0.02), DRH: 13.52 (-0.35), IPXL: 39.08 (-1.00), ZINC: 12.39 (-0.28), VSI: 41.68 (+0.76), PLL: 100.17 (-1.87), RLGY: 45.46 (-0.94), ODP: 9.30 (-0.04), PF: 36.81 (-0.25), CMCSA: 60.37 (+0.04), PCRX: 96.63 (-1.77), TOL: 36.92 (-1.00)
Will Celldex Therapeutics (CLDX) Disappoint This Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 4:00PM CST
Celldex Therapeutics (CLDX) is expected to report fourth-quarter 2014 results on Feb 24.
IPXL: 39.08 (-1.00), ISIS: 70.44 (-1.32), CLDX: 29.39 (-0.39), BMY: 65.12 (-0.93)
Why Shares of Celldex Therapeutics Inc. Skyrocketed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Feb 23, 2:24PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celldex Therapeutics shot nearly 20%...
CLDX: 29.39 (-0.39)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 11:44AM CST
HNH: 43.18 (-1.34), MELA: 1.83 (+0.02), CYBR: 59.78 (-3.09), OTIV: 1.24 (-0.02), CERU: 8.12 (+0.14), CLDX: 29.39 (-0.39), BIOC: 3.10 (-0.26), AXN: 1.49 (+0.37), SPPI: 6.26 (+0.02), NSLP: 7.65 (-0.05), RIGL: 3.56 (+0.26), VRTB: 3.61 (+0.30), WBAI: 14.50 (+0.70), BLCM: 24.48 (+0.13), SFY: 3.12 (-0.12), TSEM: 17.50 (-0.31), PTCT: 71.13 (-1.59), HOTR: 2.04 (-0.03), PRTA: 26.12 (-0.46), DGLY: 12.81 (+0.43)
CellDex Leaves Them All Behind
Scrying Biotech - at Seeking Alpha - Mon Feb 23, 10:02AM CST
CLDX: 29.39 (-0.39)
(0)
(0)